AZR
Azora Therapeutics, Inc. (DE)Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 12 ▲ 1 insider buy $100.0K at $2.75
- Jun 29 ▲ 1 insider buy $65.0K at $2.60
- Jul 9 to Jul 16 ▲ 4 days of insider buys: $41.3K by 1 insider, avg $2.76
- Nov 2 Jones Trading initiates
- Nov 2 Trading halt: Halt Resumed: AZR, trading resumed after LUDP (Volatility…
- Nov 2 Trading halt: Trading Halt: AZR · LUDP (Volatility Trading Pause)
- Nov 16 New report: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $206.3K at an average $2.70. No open-market sales. Price is 36% above their cost.
- Short sellersBUILDING
Short interest +20.9% to 217.2K shares. 4.1 days to cover, ≈8.3% of shares.
- TrendRANGE
12% below its 50-day average.
The Street
Last action Nov 2026Price is below the lowest target. Median implies +227%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Jones Trading INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Saiki Julie Chief Strategy Officer Nov 2, 2026 | CONVERT | 626,252 sh |
Davidson Matt President and CEO Nov 2, 2026 | CONVERT | 101.298 sh |
Davidson Matt President and CEO Nov 2, 2026 | CONVERT | 101,298 sh |
Saiki Julie Chief Strategy Officer Nov 2, 2026 | CONVERT | 626.252 sh |
Davidson Matt President and CEO Nov 2, 2026 | CONVERT | 524.954 sh |
Davidson Matt President and CEO Nov 2, 2026 | CONVERT | 524,954 sh |
Davidson Matt President and CEO Oct 28, 2026 | AWARD | 232,417 sh |
Davidson Matt President and CEO Oct 28, 2026 | AWARD | 333,830 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.13 | -$0.13–-$0.13 | No data | $0.00 |
| Next Q | -$0.21 | -$0.21–-$0.21 | No data | $0.00 |
| Current FY | -$4.94 | -$4.94–-$4.94 | No data | $0.00 |
| Next FY | -$0.49 | -$0.49–-$0.49 | No data | $0.00 |
Short side
FINRA· Oct 30, 2026| Nov 2, 2026 | Volatility Pause | Resumed |
| Nov 2, 2026 | Volatility Pause | Resumed |
SecBot reports
5 filings · 0 bullish · 2 bearish · 3 neutral- BEARISH S-3Nov 16, 2026
Azora Therapeutics filed a $250M universal shelf registration (S-3) including a $20M at-the-market (ATM) facility with Jefferies LLC. The company has $22M cash, a net loss of $64.6M in Q3 2026 (including a $57.1M non-cash charge), and a pre-revenue biotech pipeline with AT177 still in IND-enabling…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 12, 2026
Azora Therapeutics (formerly Adial Pharmaceuticals) reported Q3 2026 results post-merger: net loss…
Monitor the December 11, 2026 stockholder approval deadline for Series A conversion and potential $51.9M cash settlement risk. Track any milestone warrant exercise announcements for up to $32.4M in…
- NEUTRAL 3Nov 10, 2026
Three new insiders, Paul J. Hastings, Aida Habtezion, and Thomas M. Soloway, filed initial…
These Form 3 filings confirm the appointment of three new insiders but provide no ownership or transaction data. Monitor future Form 4 filings for any share acquisitions or sales by these…
- NEUTRAL 8-KNov 9, 2026
Azora Therapeutics appointed three new independent directors (Aida Habtezion, Paul Hastings…
The board overhaul and share conversion signal the completion of the Azora Therapeutics acquisition integration. Monitor for Nasdaq listing approval (pending per prior DEFA14A) and any subsequent…
All AZR filing & press-release reports (5)
- S-3 reportNov 16, 2026
- 8-K reportNov 12, 2026
- 3 reportNov 10, 2026
- 8-K reportNov 9, 2026
- SC 13G/A reportNov 3, 2026